PIMG
GERM

Patriot Investment Management Group’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Patriot Investment Management Group’s Portfolio GERM Stock Details GERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-200
Closed -$5.71K – 678
2020
Q2 		$5.71K Buy
+200
New +$5.4K ﹤0.01% 560

Other funds holding GERM

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return

Patriot Investment Management Group's GERM Position: Q3 2020 in Review

Patriot Investment Management Group sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2020, closing a stake of 200 shares — an estimated $5.71K sold.

Patriot Investment Management Group first reported a position in GERM in Q2 2020 and held it in 1 quarter. The position peaked at $5.71K in Q2 2020. 20 funds tracked by Wall St. Rank hold GERM as of Q3 2020.

  • Patriot Investment Management Group reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2020 after selling out during the quarter.
  • Patriot Investment Management Group sold 200 Amplify Treatments, Testing and Advancements ETF shares in Q3 2020, an estimated $5.71K.
  • Patriot Investment Management Group first reported a position in Amplify Treatments, Testing and Advancements ETF in Q2 2020 and held it in 1 quarter.
  • Patriot Investment Management Group's Amplify Treatments, Testing and Advancements ETF position peaked at $5.71K in Q2 2020.
  • 20 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2020.

Based on Patriot Investment Management Group's 13F filing for Q3 2020, filed 23 Oct 2020.